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Abstract: Microparticles (MPs) are extracellular vesicles (0.1–1.0 µm in size), released in response
to cell activation or apoptosis. Endothelial microparticles (EC-MP), vascular smooth muscle
cell microparticles (VSMC-MP), and macrophage microparticles (MØ-MP) are key hallmarks
of atherosclerosis progression. In our current study, we investigated the potent antioxidant
activity of baicalin to ameliorate MP-induced vascular smooth muscle cell (VSMC) dysfunction and
endothelial cell (EC) dysfunction, as well as the production of inflammatory mediators in macrophage
(RAW264.7). In our study, baicalin suppressed the apoptosis, reactive oxygen species (ROS) generation,
NO production, foam cell formation, protein expression of inducible nitric oxide synthase and
cyclooxygenase-2 in MØ-MP-induced RAW264.7. In addition, VSMC migration induced by VSMC-MP
was dose-dependently inhibited by baicalin. Likewise, baicalin inhibits metalloproteinase-9 expression
and suppresses VSMC-MP-induced VSMC proliferation by down-regulation of mitogen-activated
protein kinase and proliferating cell nuclear antigen protein expressions. Baicalin also inhibited
ROS production and apoptosis in VSMC. In EC, the marker of endothelial dysfunction (endothelial
senescence, upregulation of ICAM, and ROS production) induced by EC-MP was halted by baicalin.
Our results suggested that baicalin exerts potent biological activity to restore the function of EC and
VSMC altered by their corresponding microparticles and inhibits the release of inflammation markers
from activated macrophages.
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1. Introduction
Microparticles (MPs) are extracellular vesicles with a size ranging from 0.1 to 1.0 µm. They carry
cargo (mRNA, DNA, lipid and specific proteins) from originating cells and transfer to recipient cells,
allowing cell-to-cell communication. MP release is triggered by inducer that can cause cell apoptosis or
activation [1] and are generated by any type of body cells such as platelets, endothelial cells, leukocytes,
smooth muscle cells, and erythrocytes [2]. In the past, MPs were considered as “cell debris/dust” but
now, it is clear that MPs are not just cell debris; however, the detailed process of their generation is yet to
be elucidated [3]. Nowadays, it is known that the release of MPs from cells involves the reconstitution
of a phospholipid bilayer with the outside of the membrane exposed with phosphatidylserine and
change in the cellular organization with the disruption of cytoskeleton architecture [4]. Recently,
the role of MPs in the pathogenesis of central nervous system disorder [5], diabetes mellitus [6],
cancer [7], inflammation [8], systemic lupus erythematosus [9], endothelial dysfunctions [10] has
been explored by clinical/experimental research. In the human systemic circulation, elevated levels of
endothelial MPs (EC-MP) are linked with the progression of various cardiovascular diseases, primarily
initiated by endothelial dysfunction [11]. An in vitro study revealed that EC-MP treatment affects the
various angiogenesis parameters by reducing endothelial cell (EC) proliferation, decreasing capillary
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formation and increasing apoptosis [12]. Hidenobu Koga et al. observed a higher level of the cluster
of differentiation (CD)-144 or vascular endothelial (VE)-cadherin positive EC-MP in the systemic
circulation of patients with diabetic mellitus and coronary artery disease, including atherosclerosis.
This suggests VE-cadherin positive EC-MP in serum can be a hallmark for analyzing atherosclerosis.
Thus, various cardiovascular complications can be efficiently prevented by the therapeutics approach
in atherosclerosis patients focusing on assessments of blood CD144-EMP levels [13].
Microparticles are produced by macrophage cells in response to various stimuli such as
lipopolysaccharide (LPS), poly (I:C), actinomycin D [14,15]. LPS is a toll-like receptor (TLR)-4 ligand,
and poly (I:C) is a TLR3 ligand that can stimulate MØ-MP via TLR. MØ-MP release induced by LPS
or poly(I:C) is correlated with nitric oxide (NO) production, and treatment with the inducible nitric
oxide synthase (iNOS) inhibitor 1400W decreased particle release and NO production. Furthermore,
the treatment of RAW 264.7 cells with NO donors induced MPs production [14]. MPs from activated
macrophages could carry tumor necrosis factor-alpha (TNF-α) and contribute to the propagation
of inflammatory signals leading to myocardial infarction. Milbank E et al. hypothesized that MPs
from human carotid atherosclerotic plaques might contain active TNF-α, which could contribute to
MPs-induced inflammatory signals in human atherosclerotic lesions [15].
Pro-atherogenic inducer such as TNF-α, thrombin, and lysophosphatidylcholine can generate MPs
by vascular smooth muscle cells (VSMC) [16]. VSMC-microparticles (VSMC-MP) possesses protein
such as caveolin-1 [16] and alpha-smooth muscle actin (α-SMA) [17] obtained from originating VSMC,
making it delectable in an experimental setting by labeling VSMC-MP with either caveolin-1 or α-SMA.
EC, VSMC and macrophage are three important cell types involved in the pathogenesis of atherosclerosis
either in initiation steps or later progression of vascular inflammation [16]. G. Chiva-Blanch et al.
found that aspirin therapy inhibits vascular wall cell activation and microparticle shedding by
VSMC, suggesting a therapeutic target to lower microparticles released from cells can prevent the
progression of the disease such as diabetes mellitus and atherosclerosis [17]. Additionally, MPs
generated from apoptotic VSMC (commonly observed in atherosclerotic plaques) can, in turn, induce
endothelial dysfunction as shown by its decreased nitric oxide (NO) production and vasodilatory
capacity [18]. Previously, we have shown that VSMC-MP promotes the proliferation of VSMC through
the upregulation of the mitogen-activated protein kinase pathway (MAPK) and proliferative cell
nuclear antigen (PCNA) to facilitate vascular inflammation [19]. Similarly, in a recent review paper,
we have highlighted the role of circulating EC-MP in the progression of atherosclerosis through
oxidative stress, and upregulation of iNOS, cyclooxygenase (COX-2) and nuclear factor kappaB (NF-κB)
pathway [20]. As cell-to-cell communication mediated by cargos of microparticles has been recently
explored, there exists a potential research platform to investigate potent drug candidates that can target
various pathways to alleviate the disease progression. In this aspect, plant-based phytochemicals are
one of the emerging therapeutic alternatives.
Baicalin is a flavonoid found in Scutellaria baicalensis Georgi. It is a well-known antioxidant and
anti-inflammatory compound showing its therapeutic potential in cardiovascular diseases, diabetes,
asthma, hyperuricemia, rheumatoid arthritis, and cancer. The antioxidant activity of baicalin is
due to its potency to neutralize ROS, whereas its anti-inflammatory capacity is because of the
inhibition of the NF-κB pathway thereby attenuating the expression of several inflammatory mediators
as well as decreased expression of iNOS, COX-2, lipoxygenases, cell adhesion molecules, TNF-α,
and interleukins [21,22]. Since endothelial dysfunction, the release of inflammatory mediators
from macrophages and proliferation and migration of VSMC are key events leading to vascular
inflammation [23], we sought to target these main events of atherosclerosis progression by inducing
cells with microparticles. Therefore, the objective of this study was to evaluate the antioxidant activity
of baicalin to ameliorate vascular smooth muscle cell and endothelial dysfunction.
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2. Materials and Methods
2.1. Cell-Free In Vitro Experiments
2.1.1. Chemicals and Reagents
Baicalin was purchased from Sigma Aldrich, USA. Similarly, DPPH, ferrous sulphate,
2,2′-bipyridyl, copper sulphate, thiobarbituric acid, 1,1,3,3,-tetraethoxypropane, methanol, and butanol
were purchased from Sigma, USA. All the other chemicals and reagents were of reagent grade and
purchased from Sigma Aldrich, USA, unless stated.
2.1.2. Antioxidant Assay
DPPH radical scavenging activity, chelation assay, and TBARS assay were carried out as described
previously [24].
2.2. Cell-Based In Vitro Experiments
2.2.1. Cell Culture and Reagents
Endothelial cells were isolated from the porcine coronary artery as described previously [25].
Vascular smooth muscle cells (VSMC) were purchased from the American Type Culture Collection
(ATCC, Manassas, VA, USA), and RAW264.7 (immortalized murine macrophages cell line obtained
from BALB/c mice with Abelson murine leukemia virus-induced tumor) was purchased from the
Korean cell line bank (Seoul, Republic of Korea) and grown at 37◦C under a humidified, 5% CO2
atmosphere in Dulbecco’s modified eagle’s media (Lonza, Walkersville, MD USA) supplemented
with 10%FBS, 2mM glutamine, 100 units/mL of penicillin, 100 µg/mL of streptomycin and
2.5 µg/mL of amphotericin B. p44/42 (ERK1/2), phospho p44/42 (pERK1/2), SAPK/JNK, phospho
SAPK/JNK, p38, phospho p38, MMP-9, phospho ENOS, ENOS, phospho Akt, Akt, iNOS, COX-2
and β-actin was purchased from Cell Signalling Technology (Danvers, MA, USA). PCNA primary
antibody was purchase from Abcam (Cambridge, MA, USA). Intercellular adhesion molecule 1
(CD54/ICAM-1), Alexa488 and Alexa555 were purchase from Biocompare (San Francisco, CA,
USA). Annexin V-FITC Apoptosis Detection Kit was purchased from BioBud (Seoul, Republic
of Korea), 4’,6-diamidino-2-phenylindole (DAPI) was purchased from Thermo Fisher Scientific
(Waltham, MA, USA). 5-dodecanoylaminofluorescein di-β-d-galactopyranoside was purchased
from Invitrogen (Illkirch, France). 3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium bromide
(MTT), 2′,7′-dihydrodichlorofluorescin diacetate (DCF-DA), Oil Red O staining solution, DMSO,
phalloidin-FITC were purchased from Sigma-Aldrich (St Louis, MO, USA).
2.2.2. Isolation, Characterization, and Quantification of Microparticles.
Isolation of MPs was performed according to the protocol described by Boulanger et al., 2001 [26].
As microparticles are released by the process of cell activation or apoptosis, researchers use various
stimulants in high concentrations for high-yield production of microparticles. Gauley et al. treated
LPS at a dose ranging from 0.05 to 50 µg/mL in the RAW264.7 cell line and found the highest yield of
microparticles and a corresponding increase in nitrite (a marker of inflammation) at 50 µg/mL LPS [14].
In our study, we also use high doses of LPS for EC and RAW264.7 for the high yield of microparticles.
Briefly, confluent EC and RAW264.7 were stimulated with 10 µg/mL and 50 µg/mL LPS respectively
for 24 h. Confluent VSMC were stimulated with 20 ng/mL of TNF-α for 16 h [16]. The cell supernatant
from these stimulated cells (Five 100mm cell culture plates for each cell) was collected and subjected to
multiple centrifugation steps to obtain an MP pellet of respective cells and the process was repeated to
obtain enough MPs for all experiments. Each cell MP was pooled into a single Eppendorf tube mixed
in PBS and stored at -70◦C until further use.
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Characterization of microparticles was carried out by immunofluorescence. EC-MP was stained
with ICAM primary antibody followed by Alexa fluor-488 secondary antibody [27], VSMC-MP were
stained with α-SMA, followed by Alexa fluor-488 secondary antibody [17], and MØ-MP were stained
with annexin V-FITC as a general marker of microparticles [14]. Fluorescence images were taken at
different magnifications using confocal or microscope.
Quantification of microparticles was performed by measuring protein concentration. For each
cell microparticle, 10 µL of MP was mixed with 200 µL of 20% Bio-Rad protein assay reagent, and
absorbance of resultant blue color was read at 570nm. The protein concentration of microparticles in
terms of mg/mL was calculated with reference to the standard curve equation obtained from a serial
dilution of bovine serum albumin. For subsequent in vitro cell experiment, respective cell MPs at a
concentration of 10 µg/mL protein equivalent were used to induce the cell.
2.2.3. Cell Viability Assay
The viability of RAW 264.7 cells, VSMC and EC treated with respective MPs, and a various
dose of baicalin was determined by assaying the reduction of 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) to formazan by viable cells as described previously [24].
2.2.4. NO Production
NO production in MØ-MP-stimulated RAW 264.7 cell was determined by the Griess reagent
method as described previously [24].
2.2.5. Foam Cell Assay
Foam cell assay was carried out in RAW264.7 cell as described previously with slight
modification [24]. Oil Red O (ORO) staining was performed in oxidized-low density lipoprotein
(ox-LDL) and/or baicalin with/without 10µg/mL of MØ-MP treated RAW264.7 cell. Positive stained (red)
foam cells were observed via phase-contrast microscope (TE200; Nikon, Tokyo, Japan). Photographs
were taken at 40 ×magnification. Colorimetric quantification of lipid content in oxidized LDL and/or
MØ-MP treated RAW 264.7 cells after ORO staining was performed.
2.2.6. Western Blot
RAW264.7 cell, EC, and VSMC were treated with or without 10 µg/mL protein equivalent of
MØ-MP (for RAW264.7), 10 µg/mL protein equivalent of EC-MP (for EC), 10 µg/mL protein equivalent
of VSMC-MP (for VSMC), and various doses of baicalin. Cell lysate (30 µg/mL protein) was subjected
to SDS-PAGE for detection of the following protein; iNOS and COX-2 protein expression were detected
in RAW 264.7 cell, MAPK signaling protein, MMP-9, PCNA protein expression were detected in VSMC
and ICAM, ENOS, Akt were detected in EC by the Western blot method as described previously [24].
2.2.7. ROS Formation
a. Measurement of ROS by fluorescence intensity quantification: RAW264.7 cells, EC, VSMC
were cultured in black 96-well plate. Cells were treated with or without a various dose of baicalin
and 10 µg/mL protein equivalent of MØ-MP (for RAW264.7), 10 µg/mL protein equivalent of EC-MP
(for EC), and 10 µg/mL protein equivalent of VSMC-MP (for VSMC) for 4 h. An amount of 10 µM of
2′,7′-dihydrodichlorofluorescin diacetate was added for 60 min in the dark. Cells were washed with
PBS, and fluorescence intensity was measured at excitation 485 nm and emission 527 nm [28–30].
b. Measurement of ROS by fluorescence imaging: RAW264.7 cell, EC, VSMC was cultured in
a Cell Tek solution-coated glass slide. Cells were treated with or without a various dose of baicalin
and 10 µg/mL protein equivalent of MØ-MP (for RAW264.7), 10 µg/mL protein equivalent of EC-MP
(for EC), and 10 µg/mL protein equivalent of VSMC-MP (for VSMC) for 4 h. An amount of 10 µM of
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2′,7′-dihydrodichlorofluorescin diacetate was added for 5 min in the dark. Cells were washed with
PBS, and images were taken immediately with a fluorescence microscope [28–30].
2.2.8. Apoptosis Assay
Baicalin was treated with RAW264.7 cells, EC and VSMC at a different concentration for 1 h
followed by stimulation with 10 µg/mL protein equivalent of MØ-MP (for RAW264.7), 10 µg/mL
protein equivalent of EC-MP (for EC), and 10 µg/mL protein equivalent of VSMC-MP (for VSMC) for
24 h. Cells were centrifuged at 1500 rpm for 4 min. Supernatants were discarded was cell pellets were
washed with PBS 1 time followed by incubation of cell in Annexin V-FITC solution, prepared in 1X
binding buffer, for 30 min in the dark. After centrifugation at 1000 g for 5 min, cells were incubated
in propidium iodide prepared in 1X binding buffer for 15 min at 4◦C. Analysis of apoptosis was
performed with ArthurTM image-based cell analyzer (NanoEnTek, Seoul, South Korea) [31,32].
2.2.9. VSMC Proliferation Assay
The proliferation of VSMC, induced by VSMC-MP in the presence of various doses of baicalin,
was determined by assaying the reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) to formazan by viable cells as described previously [24]. The proliferation rate of
the control group (only VSMC-MP treated) was considered 100%, while the effect of the baicalin on
proliferation was evaluated as % of control.
2.2.10. Immunocytochemistry (PCNA Expression in VSMC and β-Galactosidase Staining in EC)
Baicalin was treated with VSMC at a different concentration for 1 h, followed by stimulation with
10 µg/mL of VSMC-MP for 24 h. Cells were washed three times with PBS and blocked with 5% BSA
followed by incubation of PCNA primary antibody in the dark overnight. After washing with PBS,
cells were incubated with Alexa 555 and DAPI secondary antibody for 1 h. Fluorescence images were
taken with a fluorescence microscope.
EC at passage one was treated with 10 µM of baicalin and/or 10 µg/mL of EC-MP for 24 h.
After pretreatment with chloroquine for 1 h, cells were labeled with 5-dodecanoylaminofluorescein
di-β-d-galactopyranoside for 1 h, washed with cold PBS, fixed with 4% buffered formalin, permeabilized
with 1% Triton X-100, blocked with 2.5% bovine serum albumin, followed by DAPI for nuclear stain.
Fluorescence images were taken at 20X magnification with a confocal microscope [33,34].
2.2.11. Gelatin Zymography
VSMC, seeded at the concentration of 5 × 105 cells in a 60 mm dish, were starved in 0.4%
FBS/DMEM for 24 h. Then, baicalin was treated at a different concentration for 1 h, followed by
stimulation with 10 µg/mL of VSMC-MP for 24 h. The conditioned medium of cells was subjected to
gelatin zymography to detect MMPs enzymatic activity as described previously [24,35].
2.2.12. Boyden Chamber Assay
VSMC migration assay was performed using a modified Boyden chamber as described previously
with slight modification. VSMC cells were seeded at a density of 1 × 105cells/mL in 200 µL of DMEM
containing 0.1% BSA in the upper chamber while the lower chamber has 600 µL of DMEM with or
without 10 µg/mL of VSMC-MP along with a different concentration of baicalin. The cells were allowed
to migrate for 48 h. The cells that had migrated to the lower face of the membrane were fixed in 10%
formalin and stained with a hematoxylin and eosin dye. The cell migration images were taken with
phase-contrast microscopy. Stained cells possessing a distinct nucleus were counted in five random
fields of view (magnification x 20) and calculated as cells per field of view [24].
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2.2.13. Wound Healing Assay
VSMC, seeded at the concentration of 5x105 cells /mL, were starved in 0.4% FBS/DMEM for 24 h.
The monolayer was scratched with a yellow tip to create a migrating zone and then washed with PBS
to remove debris. Photographs were taken at time 0. Then, 10 µg/mL VSMC-MP and baicalin at the
concentrations of 10 and 25 µM was treated for 48 h. The migrating cells were photographed by a light
microscope at the magnification of 20X [24].
2.3. Statistical Analysis
All data were expressed as mean ± SE. The significance of variance among different groups was
determined by one-way analysis of variance (ANOVA) followed by Dunnett multiple comparison test.
p-value ≤ 0.05 were considered to be significantly different.
3. Results
3.1. Characterization of Microparticles
Microparticles were successfully isolated from VSMC and macrophage and EC, in vitro. Figure 1A
represents the confocal microscopic image of in vitro isolated EC-MP stained with ICAM-Alexa 488.
Similarly, Figure 1B (copyright@American Scientific Publishers) represents the confocal image of
VSMC-MP stained with α-SMA-Alexa 488 [19]. Likewise, Figure 1C represents the confocal image of
Annexin-V-FITC labeled MØ-MP generated in vitro from macrophages (RAW264.7 cells).
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microparticles (EC-MP) (shown by arrowhead) obtained from in vitro lipopolysaccharide (LPS)-treated
endothelial cell (EC) were stained with ICAM followed by Alexa-488 and photographs were taken with
a confocal microscope at a magnification of 630 X Zoom 4. (B) Vascular smooth muscle cell (VSMC)-MP
(shown by arrowhead) obtained from tumor necrosis factor-alpha (TNF-α)-stimulated VSMC were
stained with α-smooth muscle actin (α-SMA), and photographs were taken with a confocal microscope
at a magnification of 630 X Zoom. (C) Macrophage microparticles (MØ-MP) obtained from LPS treated
macrophage (RAW264.7) were stained with Annexin V-FITC, and photographs were taken with a
confocal microscope at a magnification of 630 X Zoom 4.
3.2. Baicalin Inhibits NO Production, iNOS, and COX-2 Protein Expression in MØ-MP Induced RAW264.7 Cell
Firstly, we evaluated the RAW264.7 cell viability after treatment with various doses of baicalin
and MØ-MP. As shown in Figure 2A, baicalin, at a dose of up to 25 µM, did not alter the RAW264.7
cell viability compared to normal (baicalin untreated group). Figure 2B shows the efficacy of baicalin
to inhibit the NO production in MØ-MP induced RAW264.7 cells, whereas Figure 2C–E shows the
potency of baicalin to reduce the protein expression of iNOS and COX-2.
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3.3. Baicalin Inhibits MØ-MP Induced ROS Production, Apoptosis and Foam Cell Formation in RAW264.7 Cell
As shown in Figure 3A,B, baicalin dose-dependently inhibited the ROS production in MØ-MP
induced RAW264.7 cell. In consistence with a decrease in ROS production, there was a dose-dependent
inhibition of RAW264.7 cell apoptosis by baicalin (Figure 3C). Similarly, the oxidized-LDL intake by
RAW264.7 is increased by treatment with MØ-MP revealed by increased intensity of Oil Red O-staining
of the cell. However, baicalin, at a dose of 25 µM, decreased the ox-LDL intake (Figure 3D). Consistently,
the lipid quantification after foam cell assay shows the high lipid content in RAW264.7 cells treated with
ox-LDL and MØ-MP whereas baicalin decreased the lipid accumulation inside RAW264.7 (Figure 3E).
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Figure 3. Effect of baicalin on MØ-MP induced reactive oxygen species (ROS) production, apoptosis,
and foam cell formation in RAW264.7. (A) RAW264.7 cell was treated with or without MØ-MP and a
various dose of baicalin for 24 h. DCF-DA was treated to detect the ROS produce by activated RAW264.7
indicated by green fluorescence. Image was taken at 20×magnification. (B) ROS fluorescence intensity
was measured at excitation 485 nm and emission 527 nm. (C) RAW264.7 cell was treated with or
without MØ-MP and a various dose of b icalin for 24 h. Apoptosis assay of RAW264.7 cell measured
by Annexin V-FITC staining. (D) RAW264.7 cell was treated with or without ox-LDL, MØ-MP and
baicalin. The ox-LDL engulfed by cells was measured by Oil Red O staining. (E) After ORO, the
cell was rinsed with 60% isopropyl alcohol, and the lipid content was quantified. Each value is the
mean ± SE of three to five independent experiments and each independent experiment contains five
replicates. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control (MØ-MP alone). The analysis
was performed using one-way ANOVA followed by Dunnett multiple comparison test.
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3.4. Baicalin Target the Endothelial Dysfunction Marker to Restore EC Function
Firstly, we evaluated the EC cell viability by the treatment of various doses of baicalin and EC-MP.
As shown in Figure 4A, baicalin, at a dose up to 10 µM, did not alter the EC viability compared
to normal (baicalin untreated group). Similarly, Figure 4B shows the results of EC-MP induced EC
apoptosis. Although EC-MP slightly increases the apoptosis of EC, baicalin slightly decreases the
apoptosis of EC, however, there was no statistically significant difference. Endothelial dysfunction
results in altered protein expression by EC. As shown in Figure 4C, the protein expression of ICAM
was increased, whereas pENOS and pAKT were decreased by EC-MP treatment. In contrast, baicalin
treatment results in a significant decrease in protein expression of ICAM and a slight increase in pAKT
but no significant difference in pENOS expression (Figure 4D–F). Similarly, the production of ROS in
response to EC-MP was increased in EC, while baicalin dose-dependently inhibited the ROS generation
(Figure 4G,H). Likewise, EC-MP induced the senescence of EC as revealed by an increase in senescence
induced β-galactosidase positive fluorescence staining while baicalin at a dose of 10 µM significantly
decrease the β-galactosidase staining (Figure 4I)
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Figure 4. Effect of baicalin on endothelial dysfunction marker. (A) EC was incubated with EC-MP
and various doses of baicalin for 24 h, followed by MTT solution for 4 h. The absorbance of purple
formazan was taken at 540 nm. (B) EC treated with or without EC- P, and a various dose of baicalin
was incubated with Annexin V-FITC followed by propodium iodide. Analysis of EC apoptosis was
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carried out with ArthurTM image-based cell analyzer. (C) The cell lysate of EC treated with or
without EC-MP and various doses of baicalin for 24 h was subjected to SDS-PAGE for the detection
of ICAM, pENOS, and pAkt protein expression by Western blot. β-actin was used for normalization.
(D) Quantitative data of ICAM fold change. (E) Quantitative data of pENOS fold change. (F) Quantitative
data of pAkt fold change. (G) EC was treated with or without EC-MP and a various dose of baicalin
for 24 h. DCF-DA was treated to detect the ROS produce by EC indicated by green fluorescence.
Images were taken at 20×magnification. (H) ROS fluorescence intensity was measured at excitation
485 nm and emission 527 nm. (I) EC treated with EC-MP and/or baicalin were labeled with the
β-galactosidase (green) and incubated with DAPI for nuclear stain (blue). Fluorescence images were
taken at 20× magnification with a confocal microscope. Each value is the mean ± SE of three to
four independent experiments, and each independent experiment contains five replicates. * p < 0.05,
** p < 0.01, **** p < 0.0001 vs. control (EC-MP alone). The analysis was performed using one-way
ANOVA followed by Dunnett multiple comparison test.
3.5. Baicalin Inhibits Proliferation of VSMC Induced by VSMC-MP
Initially, we evaluated the VSMC cell viability by treatment of various doses of baicalin along with
VSMC-MP. As shown in Figure 5A, baicalin, at a dose up to 25 µM did not alter the VSMC viability as
compared to normal (baicalin untreated group). VSMC-MP cause approximately 25% more proliferation
of VSMC than the normal group (VSMC-MP untreated). However, baicalin inhibited the proliferation
of VSMC in a dose-dependent manner (Figure 5b). Consistently, the increase in PCNA expression (a
marker of VSMC proliferation) by VSMC-MP was inhibited by baicalin in both Western blot (Figure 5C,D)
and immunofluorescence experiments (Figure 5E). The overexpression of MAPK signaling pathway
proteins is responsible for VSMC proliferation [24]. As shown in Figure 5F, the increase in MAPK protein
expression-induced VSMC-MP was inhibited with baicalin treatment. There was a dose-dependent
inhibition of pERK 1/2 (Figure 6G), pJNK (Figure 6H), and pP38 (Figure 6I) by baicalin.
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Figure 5. Effect of baicalin on VSMC-MP induced proliferation of VSMC. (A) VSMC were incubated with
VSMC-MP and a various dose of baicalin for 48 h, followed by MTT solution for 4 h. The absorbance of
purple formazan was taken at 540nm. (B) VSMC incubated with or without VSMC-MP and various doses
of baicalin for 48 h were evaluated for proliferation by MTT method. (C) The cell lysate of VSMC treated
with or without VSMC-MP and various doses of baicalin for 24 h and was subjected to SDS-PAGE for the
Antioxidants 2020, 9, 890 14 of 23
detection of proliferative cell nuclear antigen (PCNA) protein expression by Western blot. β-actin was
used for normalization. (D) Quantitative data of PCNA fold change. (E) VSMC were incubated with or
without VSMC-MP and baicalin for 24 h. VSMC were exposed to PCNA primary antibody followed
by Alexa 555 and incubated with DAPI for nuclear stain. Fluorescence images were taken at 10X
magnification with a fluorescence microscope. (F) VSMC were incubated with or without VSMC-MP
and baicalin for 1 h. The cell lysate was subjected to SDS-PAGE for the detection of a phosphorylated
and non-phosphorylated form of ERK1/2, p38, JNK protein expression by Western blot. β-actin was
used for normalization. (G) Quantitative data of pERK1/2-fold change. (H) Quantitative data of
pJNK fold change. (I) Quantitative data of pP38 fold change. Each value is the mean ± SE of three to
four independent experiments, and each independent experiment contains five replicates. * p < 0.05,
** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control (VSMC-MP alone). The analysis was performed
using one-way ANOVA followed by Dunnett multiple comparison test.
3.6. Baicalin Inhibits VSMC Migration Induced by EC-MP and VSMC-MP
VSMC-MP increases both enzymatic activity and protein expression of MMP-9, respectively,
in VSMC. However, the treatment of baicalin showed dose-dependent inhibition in both gelatin
zymography (Figure 6A) and Western blot analysis (Figure 6B,C). In the Boyden chamber assay,
VSMC-MP stimulated the migration of VSMC from the upper chamber to the lower chamber. However,
baicalin was successful in halting the VSMC migration (Figure 6D,E). Consistently, in another model of
cell migration (wound healing assay), baicalin significantly reduced the migration of VSMC to the
artificially created wound (migration area) in a dose-dependent manner (Figure 6F).
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Figure 6. Effect of baicalin on VSMC-MP induced VSMC migration. VSMC were incubated 
with or without VSMC-MP and baicalin for 24 hours. (A) Cell supernatant media was subjected to 
gelatin zymography for the detection of MMP enzymatic activity. (B) Cell lysate was subject to 
Western blot for protein expression of MMP-9. β-actin was used for normalization. (C) Quantitative 
data of MMP-9-fold change. (D) VSMCs were induced to migrate through the gelatin membrane 
barrier in the presence of baicalin and VSMC-MP for 48 h. Images of migrated VSMC were taken after 
H/E staining (20× magnification). (E) The cells on the outer layer after migration were counted in five 
random positions under the high-power field (HPF). (F) The monolayer of confluent VSMC was 
scratched to create a migrating zone. Photographs were taken at time 0. Then, baicalin was treated at 
the concentrations of 10 and 25 μM for up to 48 h in the presence of VSMC-MP. Photographs were 
taken at 24 h and 48 h (20× magnification). Each value is the mean ± SE of three to five independent 
experiments, and each independent experiment contains five replicates. ***p < 0.001, ****p < 0.0001 vs. 
control (VSMC-MP alone). The analysis was performed by one-way ANOVA followed by Dunnett 
multiple comparison test. 
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Fig . ff ct of baicalin on VSMC-MP induced VSMC migrat on. VSMC were incubated with
or withou VSMC- P and baicalin for 24 h. (A) Cell supernatant media was subjected to g la in
zymography for t e detec ion of MMP enzymatic activity. (B) Cell lysate was subject to We tern blot f r
protein expression f MMP-9. β-actin was used for normalization. (C) Quantitative data of MMP-9-fold
ch nge. (D) VSMCs were induced to migrate through the gelatin membrane barri r in the prese ce
of baicalin and VSMC-MP for 48 h. Images of migrated VSMC were t k n after H/E staining (20×
magnification). (E) The cells the outer layer after migration were counted in fiv random positions
u er the high-power field (HPF). (F) The monolayer of confluent VSMC was scratched to create a
migrating zone. Photographs were taken at time 0. Then, baicalin was treated at the concentrations
of 10 and 25 µM for up to 48 h in the presence of VSMC-MP. Photographs were taken at 24 h and
48 h (20× magnification). Each value is the mean ± SE of three to five independent experiments,
and each independent experiment contains five replicates. *** p < 0.001, **** p < 0.0001 vs. control
(VSMC-MP alone). The analysis was performed by one-way ANOVA followed by Dunnett multiple
comparison test.
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3.7. Baicalin Inhibits ROS Production and Apoptosis in VSMC-MP Induced VSMC
Figure 7A shows the activity of baicalin to inhibit ROS production in VSMC-MP-induced VSMC.
There was a 4.5-fold increase in ROS production after SMC-MP treatment as compared to the normal
group, whereas baicalin dose-dependently reduced the cellular ROS level (Figure 7B). Similarly, the
apoptosis of VSMC was increased 5.5-fold, while baicalin treatment decreases the VSMC apoptosis
rate (Figure 7C).
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3.8. Antioxidant Activity of Baicalin
Baicalin scavenges the DPPH free radical in a dose-dependent manner with an IC50 of 27.21 µM
(Figure 8A). Similarly, baicalin also inhibits the lipid peroxidation induced by CuSO4 with an IC50 of
95.09 µM. (Figure 8B). Likewise, baicalin possesses significant metal-chelating potency with an IC50
of 352.04 µM (Figure 8C). This potent antioxidant potency of baicalin could be the possible reason to
inhibit the ROS formation in all three cell lines (VSMC, EC, MØ) in vitro.
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inflammation mediator release from the macrophage. Various cell signaling pathways were targeted 
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VSMC proliferation such as MAPKs pathway, PCNA expression) and macrophages (NO production, 
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4. Discussion
In our previous study, we provided a lot of evidence of VSMC migration and proliferation and
release of inflammatory mediators by activated macrophage leading to the progression of vascular
inflammation/atherosclerosis [23,24,36–43]. In those studies, we used an inducer such as TNF-α
or PDGF or lysophosphatidic acid to stimulate VSMC migration and proliferation, and LPS for
inflammation mediator release from the macrophage. Various cell signaling pathways were targeted
in VSMC (pathway of VSMC migration such as MMP-9, cytoskeletal remodeling, and pathway of
VSMC proliferation such as MAPKs pathway, PCNA expression) and macrophages (NO production,
COX-2, iNOS expression in RAW264.7 cell to prevent the vascular inflammation). In the current
study, we use the same inducer (TNF-α -and LPS) to induce microparticle release from VSMC, EC,
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and MØ to reveal the progression of vascular inflammation by exposing cells with their respective
microparticles. Microparticles were successfully isolated from established methods, and they were
used for various cell-based assays to reveal their role in vascular inflammation targeting multiple cell
signaling pathways.
The MAPK protein family includes ERK1/2, JNK, and p38, which are actively involved in the
proliferation and migration of VSMC leading to intimal hyperplasia [41]. In our study, VSMC-MP
induced proliferation of VSMC, as shown by the results of the MTT assay and upregulation of MAPK
and PCNA protein expression. The treatment of baicalin dose-dependently inhibited the proliferation
of VSMC. Similarly, VSMC-MP induced the migration of VSMC in a modified Boyden chamber assay
and wound healing assay. VSMC migration was supported by the overexpression of MMP-9 by
VSMC-MP. MMP-9 can degrade the extracellular matrix barrier, thereby facilitating the migration of
VSMC [36]. In contrast, the treatment of baicalin inhibited the VSMC migration by targeting MMP-9
in a dose-dependent manner. Furthermore, VSMC-MP increased the generation of ROS in VSMC
approximately five-fold compared to the untreated group, which is consistent with the same fold
of increase in apoptosis of VSMC by VSMC-MP. However, baicalin halted the ROS production and
slowed down the apoptosis of VSMC in a dose-dependent manner. One of the reasons to halt the
ROS production is because of the potent anti-oxidation activity of baicalin, as shown in our cell-free
antioxidant assay (Figure 8A-C). Since microparticles are generated either by cell activation or by cell
apoptosis [1], it is possible that by slowing the rate of apoptosis, baicalin can decrease the further
microparticle release.
Vascular inflammation is exaggerated by inflammation mediators released by activated
macrophages. RAW264.7 is a murine macrophage cell line widely used in the study of atherosclerosis
as they play a crucial role in the progression of vascular inflammation through the overproduction of
various inflammation mediators [44]. These mediators include excessive NO release via iNOS pathway
in response to stimuli such as LPS, overexpression of COX-2 producing inflammatory prostaglandin,
NF-κB translocation from cytosol to nucleus, the release of TNF-α and IL-6 [24]. LDL in the blood
can easily undergo oxidation by ROS to produce oxidized-LDL, which is engulfed by an activated
macrophage and accumulates in a significant amount as a fatty streak, later changing into a foam
cell, which is commonly present in atherosclerotic plaque [45,46]. In our study, MØ-MP increases the
expression of iNOS and correspondingly increases the production of NO in RAW264.7. Moreover,
there was also an increase in COX-2 protein expression, production of ROS, and formation of foam
cells in MØ-MP-stimulated RAW264.7. In contrast, the treatment of baicalin remarkably inhibited all
these inflammatory mediators.
Endothelial dysfunction is a result of an imbalance between endogenous vasodilator and
vasoconstrictor agent. Specifically, the reduction in NO release via the ENOS pathway affects the
endothelium-dependent vasorelaxation, a characteristic feature of vascular dysfunction [47]. Damage
to the healthy endothelial cells is caused by various noxious agents such as bacterial LPS, ROS, TNF-α,
myeloperoxidase and other inflammatory cytokines released by macrophage or neutrophil. All of this
agent can trigger EC aging and apoptosis, followed by EC-MP generation. These EC-MP then facilitate
the progression of vascular inflammation [20]. EC-MP induce EC aging (senescence), which leads to a
decrease in NO production via the ENOS and AKT pathways [31]. We observed that the 24hr treatment
of EC-MP to EC leads to senescence of cells (revealed by intense β-galactosidase positive staining).
In contrast, the treatment of baicalin significantly decreases the β-galactosidase staining (Figure 1).
Furthermore, EC-MP expresses the cell adhesion molecules such as ICAM-1, VCAM, PECAM-1, and
VE-cadherin [6,15] possessed from the parent cell which makes them potent inducers of EC dysfunction
by facilitating the adhesion of circulating cells such as macrophages to the EC. In the cultured EC,
it is reported that the production of NO is controlled by Akt-dependent phosphorylation of eNOS.
EC-derived NO helps to maintain vascular homeostasis. Therefore, the inhibition of the Akt pathway
or mutation of Akt site on eNOS protein could prevent activation of eNOS leading to altered vascular
tone and endothelial function [48].
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The detailed mechanism of vascular inflammation induced by various microparticles is shown
in Figure 9. In our study, EC-MP induced most of the markers of EC dysfunction when treated
with EC. The overexpression of ICAM and reduced expression of pAkt by EC-MP was reversed by
baicalin treatment. Furthermore, the production of ROS and senescence of EC was also inhibited by
baicalin. Collectively, our results support the fact that bacalin lowers the vascular inflammation by
targeting abnormalities in three key cell types (EC, VSMC, and MØ) involved in the pathogenesis of
vascular inflammation/atherosclerosis. The concept of microparticles inducing disease progression is
considered new. Recently, researchers have been studying the various herbal interventions and synthetic
compounds to explore the activity of these promising drug candidates to target microparticle-mediated
pathological conditions.
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Figure 9. Mechanism of vascular inflammation mediated by microparticles and target of baicalin.
Endothelial cell (EC), vascular smooth muscle cell (VSMC), and macrophage cell activation in response to
various stimuli such as ROS, LPS, tumor necrosis factor (TNF)-α, interleukin (IL) lead to the production
of endothelial microparticle (EC-MP), smooth muscle cell-microparticles (VSMC-MP) and macrophage
microparticles (MØ-MP) respectively. EC-MP increases the ROS production in EC, thereby reduce
phosphorylated ENOS and Akt expression followed by a decrease in nitric oxide (NO) production (a
potent vasorelaxant). VSMC-MP stimulates VSMC to express matrix metalloproteinase-9 (MMP-9),
leading to the degradation of the elastic lamina barrier and ease VSMC migration to the site of the
atherosclerotic lesion. Furthermore, VSMC-MP also upregulates the mitogen-activated protein kinase
pathway (MAPK) (ERK, JNK, P38) pathway and PCNA protein expression leading to proliferation
and migration of VSMC to develop vascular inflammation. EC-MP and platelet microparticles (PMPs)
possesses cell adhesion molecules that support the adhesion of various circulating cell the endothelial
cell followed by altered intimal permeability and vascular lesion at a later stage. MØ-MP activated
macrophage to uptake oxidized LDL and change in foam cell. This activated form of macrophage is
responsible for the overexpression of nitric oxide (NO) and the procoagulant factor causing vascular
inflammation. As a whole, all of this pathway leads to atherosclerosis. The target of baicalin to inhibit
vascular inflammation is shown by the red line.
A recent study has shown that dietary flavanol intervention lowers endothelial microparticles with
an improvement in endothelial function in coronary artery patients [49]. However, this study could
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not reveal the specific mechanism followed by flavonol to improve endothelial function. Kam et al.
showed that curcumin reduced microparticle release from endothelial cells. However, there was no
clear indication that endothelial microparticles can act like TNF-α to cause the overexpression of cell
adhesion molecules, which is an important parameter during vascular inflammation [50]. Another
study by Schwarz et al. stated that red wine prevents the acute negative vascular effect of smoking.
This clinical study concludes that smoking leads to elevation of endothelial-, platelet-, monocyte-,
and leukocyte-derived microparticles while consumption of red wine lowers the microparticle levels.
However, this study’s limitation was a lack of evidence to prove the exact molecular mechanism of
how the levels of microparticles were lowered by the beneficial activity of red wine [51]. Nevertheless,
these herbal candidates can be a potential option for preventing disease caused by the overproduction
of microparticles. Our study showed the molecular mechanism followed by baicalin to target various
pathways in cell types (EC, VSMC and MØ) involved in vascular inflammation. Taken together, our
finding suggests baicalin as a promising compound with the potential to ameliorate the features of
vascular inflammatory disease. However, our study has few limitations, and it opens the platform for
further studies and guidance for researchers working with microparticles. First, all our evidence is
experimental data from in vitro studies from various cell lines. It would be more interesting to study
and validate the in vitro finding with the clinical setting of vascular inflammation/atherosclerosis by
carrying out experiments in primary cells isolated from the healthy controls and patients with acute
coronary studies. Second, the levels of microparticles are high in the diseased state but not the same in
all individuals. Therefore, it is difficult to find the exact clinically relevant dose of microparticles that
can induce the features of vascular inflammation in in vitro experiments. It is essential to carry out the
dose–titration study to investigate the clinical relevance dose of microparticles in various disease states
before carrying out the in vitro and animal model studies.
5. Conclusions
Baicalin possesses potent antioxidant activity, inhibiting VSMC-MP-induced VSMC proliferation
via the PCNA and MAPK signaling pathways, and migration via the inhibition of MMP-9. Baicalin also
attenuated the MØ-MP-induced vascular inflammation by the downregulation of potent inflammatory
mediators; NO, ROS, iNOS, COX-2, and foam cell formation in RAW264.7. Baicalin inhibits endothelial
dysfunction by downregulating ROS production and ICAM expression while upregulating pENOS
and pAkt in endothelial cells. These signify that baicalin can be a potential therapeutic option for the
prevention of vascular inflammatory disorders such as atherosclerosis.
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